Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Anti-myelin-associated glycoprotein IgM autoantibody (Anti-MAG IgM)
- Target
- Anti-MAG IgM
- Molecular classification
- Autoantibody, Immunoglobulin, Glycan-binding antibody
01
Overview
Anti-myelin-associated glycoprotein (MAG) IgM autoantibodies are IgM class autoantibodies that target myelin-associated glycoprotein, a component of the myelin sheath in the peripheral nervous system. These antibodies are pathogenic and associated with autoimmune demyelinating neuropathy. They disrupt axon-Schwann cell interactions and impair myelination, leading to demyelination and axonal loss. They are detected in patients with slowly progressive distal sensory or sensorimotor neuropathies and may be associated with MGUS or Waldenström's macroglobulinemia. Diagnosis involves measuring serum antibody levels, and treatment options are limited with variable efficacy.
- Other names
- IgM anti-MAG antibodyAnti-MAG antibodyAnti-myelin associated glycoprotein IgM antibodyIgM anti-myelin-associated glycoprotein antibody
02
Mechanism of action
IVIG: Modulation of the immune system; Plasma exchange: Removal of antibodies; Rituximab: B-cell depletion; Lenalidomide: Immunomodulatory; BTKi: Inhibition of B-cell signaling
03
Biological functions
Autoimmune responseDemyelinationAntibody-mediated cytotoxicity (possible)
04
Disease associations
Anti-MAG neuropathyDemyelinating neuropathyMonoclonal gammopathy of undetermined significance (MGUS)-associated neuropathyWaldenström's macroglobulinemia-associated neuropathy
05
Safety considerations
Variable treatment responseLimited long-term efficacy of current therapiesAdverse events associated with cytotoxic therapiesInfusion reactions (IVIG, Rituximab)Risk of infection (Rituximab, cytotoxic therapies)Thromboembolic events (Lenalidomide)Adverse events (Lenalidomide)
06
Interacting drugs
Intravenous immunoglobulin (IVIG)
4 more in the full profile.
07
Biomarkers
Serum anti-MAG IgM antibody titerHNK-1 epitope expression on MAG
Beyond the preview
Go deeper on Anti-myelin-associated glycoprotein IgM autoantibody (Anti-MAG IgM).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Anti-myelin-associated glycoprotein IgM autoantibody (Anti-MAG IgM).